Jubilant Ingrevia Limited (JUBLINGREA.NS)
INR 688.7
(7.2%)
INR 688.7
(7.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 19.94 Billion INR | 25.23% |
| 2022 | 15.92 Billion INR | 16.76% |
| 2021 | 13.64 Billion INR | -6.29% |
| 2020 | 14.55 Billion INR | 878344.18% |
| 2019 | 1.65 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 20.25 Billion INR | 174.01% |
| 2024 Q1 | -27.37 Billion INR | -237.26% |
| 2023 FY | 19.94 Billion INR | 25.23% |
| 2023 Q4 | 19.94 Billion INR | 0.0% |
| 2023 Q2 | 17.7 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 15.48 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 15.92 Billion INR | 16.76% |
| 2022 Q4 | 15.92 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 13.64 Billion INR | -6.29% |
| 2021 Q4 | 13.64 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 13.5 Billion INR | 0.0% |
| 2020 FY | 14.55 Billion INR | 878344.18% |
| 2020 Q4 | 14.55 Billion INR | 848635.86% |
| 2020 Q3 | 1.71 Million INR | 0.0% |
| 2019 FY | 1.65 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biocon Limited | 307.95 Billion INR | 93.524% |
| Blue Jet Healthcare Limited | 2.13 Billion INR | -833.617% |
| Concord Biotech Limited | 1.74 Billion INR | -1045.804% |
| Dishman Carbogen Amcis Limited | 39.53 Billion INR | 49.558% |
| Lyka Labs Limited | 884.58 Million INR | -2154.634% |
| Panacea Biotec Limited | 4.02 Billion INR | -396.1% |
| Piramal Pharma Limited | 74 Billion INR | 73.05% |
| SMS Lifesciences India Limited | 1.96 Billion INR | -912.999% |
| Supriya Lifescience Limited | 1.05 Billion INR | -1783.839% |
| Syngene International Limited | 18.93 Billion INR | -5.308% |
| TAKE Solutions Limited | 969.78 Million INR | -1956.57% |
| Zota Health Care Limited | 1.38 Billion INR | -1341.556% |